{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:50Z","timestamp":1792239050401,"version":"4.4.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The identification and targeting of B-cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates, chimeric antigen receptor T cells, and T-cell engagers have revolutionized the care of patients with multiple myeloma (MM). These treatment modalities have improved the survival outcomes of patients with relapsed and\/or refractory MM compared with previously established strategies and are moving into earlier lines of therapy. Despite their efficacy, the majority of patients eventually relapse, necessitating additional therapeutic targets for salvage. G-protein\u2013coupled receptor class 5 member D, Fc receptor-homolog 5, and SLAMF7 are some examples of novel targets in development. This expanding armamentarium of immunotherapeutic agents will be crucial to address the unmet need for relapses after BCMA-targeting therapies, particularly antigen-negative relapses. The utilization of sequential T-cell redirective therapies including agents targeting different tumor-associated antigens and combination therapies appears feasible, paving the way for effective chemotherapy-free regimes. Deliberate consideration of treatment timing, preserving T-cell health, overcoming antigenic loss, and comprehension of the complex tumor microenvironment would be key to maximizing therapeutic benefits and minimizing adverse effects. This review summarizes novel targets in development for myeloma beyond BCMA, presenting pivotal safety and efficacy data derived from clinical trials when available and the considerations vital for navigating this expanding landscape of immunotherapeutic options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010856","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:02:02Z","timestamp":1718226122000},"page":"4433-4446","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Beyond BCMA: newer immune targets in myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-1447","authenticated-orcid":false,"given":"Melinda S. Y.","family":"Tan","sequence":"first","affiliation":[{"name":"1Department of Haematology, Singapore General Hospital, Singapore"},{"name":"2Department of Haematology, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-3474","authenticated-orcid":false,"given":"Yunxin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Singapore General Hospital, Singapore"},{"name":"2Department of Haematology, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"issue":"3","key":"2024082712452718200_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2024082712452718200_bib2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3324\/haematol.2021.280424","article-title":"Improved survival in myeloma patients-a nationwide registry study of 4,647 patients \u226575 years treated in Denmark and Sweden","volume":"108","author":"Moore","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2024082712452718200_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024082712452718200_bib4","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024082712452718200_bib5","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"16 suppl","key":"2024082712452718200_bib6","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2023.41.16_suppl.8007","article-title":"A\u00a0phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): DREAMM","volume":"41","author":"Weisel","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024082712452718200_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024082712452718200_bib8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024082712452718200_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024082712452718200_bib10","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2024082712452718200_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024082712452718200_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024082712452718200_bib13","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.3390\/cancers15112891","article-title":"Outcomes of penta-refractory multiple myeloma patients treated with or without BCMA-directed therapy","volume":"15","author":"Atrash","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"17 suppl","key":"2024082712452718200_bib14","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024082712452718200_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2024082712452718200_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11899-022-00675-3","article-title":"Bispecific antibodies for the treatment of multiple myeloma","volume":"17","author":"Goldsmith","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2024082712452718200_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2024082712452718200_bib20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024082712452718200_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024082712452718200_bib22","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024082712452718200_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J\u00a0Cell Immunother"},{"issue":"1","key":"2024082712452718200_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A\u00a0bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024082712452718200_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"2024082712452718200_bib67","first-page":"1","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"16 suppl","key":"2024082712452718200_bib24","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16 suppl","key":"2024082712452718200_bib25","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal)\u00a0+ daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2024082712452718200_bib68","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S2152-2650(23)01648-8","article-title":"P-030 first results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"23","author":"Magen","year":"2023","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"suppl 1","key":"2024082712452718200_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712452718200_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"485","key":"2024082712452718200_bib18","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"2024082712452718200_bib19","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2024082712452718200_bib23","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16 suppl","key":"2024082712452718200_bib26","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024082712452718200_bib27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2022-157485","article-title":"RG6234: a novel 2:1 GPRC5D T cell bispecific antibody exhibits best in class potential for the treatment of multiple myeloma as a monotherapy and in combination","volume":"140","author":"Eckmann","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712452718200_bib29","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2021-153817","article-title":"Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab (JNJ-64407564) for the treatment of relapsed and\/or refractory multiple myeloma","volume":"138","author":"Mancia","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2024082712452718200_bib30","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A\u00a0T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024082712452718200_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024082712452718200_bib32","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"2024082712452718200_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024082712452718200_bib34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"issue":"4","key":"2024082712452718200_bib35","first-page":"59","article-title":"UCARTCS1A, an allogeneic CAR T-cell therapy targeting CS1 in patients with relapsed\/refractory multiple myeloma (RRMM): preliminary translational results from a first-in-human phase I trial (MELANI-01)","volume":"29","author":"Patel","year":"2021","journal-title":"Molecular Therapy"},{"issue":"9","key":"2024082712452718200_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"issue":"26","key":"2024082712452718200_bib37","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024082712452718200_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"10","key":"2024082712452718200_bib39","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"2024082712452718200_bib41","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2024082712452718200_bib42","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-16-0232","article-title":"Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by SynstatinIGF1R inhibits tumor growth","volume":"76","author":"Beauvais","year":"2016","journal-title":"Cancer Res"},{"issue":"6","key":"2024082712452718200_bib43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"11","key":"2024082712452718200_bib44","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1\/2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol"},{"key":"2024082712452718200_bib46","doi-asserted-by":"crossref","first-page":"4928315","DOI":"10.1155\/2019\/4928315","article-title":"Prevalence of Syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues","volume":"2019","author":"Kind","year":"2019","journal-title":"Dis Markers"},{"issue":"20","key":"2024082712452718200_bib47","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.3390\/molecules25204844","article-title":"The circular life of human CD38: from basic science to clinics and back","volume":"25","author":"Horenstein","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"2024082712452718200_bib48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"2024082712452718200_bib49","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A\u00a0rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"2024082712452718200_bib50","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"2024082712452718200_bib51","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin \u03b27 is a novel multiple myeloma\u2013specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"issue":"7","key":"2024082712452718200_bib52","doi-asserted-by":"crossref","first-page":"101110","DOI":"10.1016\/j.xcrm.2023.101110","article-title":"A\u00a0target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma","volume":"4","author":"Di Meo","year":"2023","journal-title":"Cell Rep Med"},{"issue":"suppl 1","key":"2024082712452718200_bib53","doi-asserted-by":"crossref","first-page":"9961","DOI":"10.1182\/blood-2022-168968","article-title":"Development of the first SEMA4A CAR-T cell targeting multiple myeloma","volume":"140","author":"Roy","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024082712452718200_bib54","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2024082712452718200_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"2024082712452718200_bib56","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1158\/0008-5472.CAN-05-2474","article-title":"MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin","volume":"65","author":"Huang","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"2024082712452718200_bib57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bjh.14493","article-title":"Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1","volume":"176","author":"Bar-Natan","year":"2017","journal-title":"Br J Haematol"},{"key":"2024082712452718200_bib58","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S2152-2650(21)02352-1","article-title":"P-225: a first-in-human study of FOR46 in patients with triple refractory multiple myeloma","volume":"21","author":"Wong","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2024082712452718200_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A\u00a0phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"102","key":"2024082712452718200_bib60","doi-asserted-by":"crossref","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"2024082712452718200_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bcp.2019.07.015","article-title":"Intracellular targets as source for cleaner targets for the treatment of solid tumors","volume":"168","author":"Gerber","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2024082712452718200_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/cells12010027","article-title":"The intracellular proteome as a source for novel targets in CAR-T and T-cell engagers-based immunotherapy","volume":"12","author":"Arman","year":"2022","journal-title":"Cells"},{"issue":"15 suppl","key":"2024082712452718200_bib63","doi-asserted-by":"crossref","first-page":"TPS8555","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8555","article-title":"Open-label pilot study of genetically engineered NY-ESO-1\u2013specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed\/refractory multiple myeloma","volume":"38","author":"Rapoport","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024082712452718200_bib64","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024082712452718200_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","article-title":"Ex\u00a0vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma","volume":"4","author":"Kropivsek","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"2024082712452718200_bib70","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood cancer Discov"},{"issue":"suppl 1","key":"2024082712452718200_bib71","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2022-170686","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma: an updated clinical study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"16 suppl","key":"2024082712452718200_bib72","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024082712452718200_bib73","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"suppl 1","key":"2024082712452718200_bib74","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2021-152160","article-title":"Preclinical assessment of CDR101 - a BCMAxCD3xPD-L1 trispecific antibody with superior anti-tumor efficacy","volume":"138","author":"Vrohlings","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712452718200_bib75","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2022-159353","article-title":"ISB 2001, a first-in-class trispecific BCMA and CD38\u00a0T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens","volume":"140","author":"Pihlgren","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712452718200_bib76","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2021-145586","article-title":"ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of relapsed refractory multiple myeloma","volume":"138","author":"Stefano","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024082712452718200_bib77","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematology"},{"issue":"8","key":"2024082712452718200_bib78","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41409-018-0403-2","article-title":"A\u00a0retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"54","author":"Hu","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024082712452718200_bib79","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2024082712452718200_bib80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 1","key":"2024082712452718200_bib81","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024082712452718200_bib82","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2024082712452718200_bib83","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"2024082712452718200_bib84","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2024082712452718200_bib85","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024082712452718200_bib86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"2024082712452718200_bib87","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"10297","key":"2024082712452718200_bib88","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London, England)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4433\/2239700\/blooda_adv-2023-010856-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4433\/2239700\/blooda_adv-2023-010856-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:46:13Z","timestamp":1724762773000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4433\/516505\/Beyond-BCMA-newer-immune-targets-in-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":88,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010856","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}